Transcript Prescribed Drug Spending, Canada, 2001 to 2013 f

Canadian Institute for Health Information
1
Prescribed Drug Spending
in Canada, 2012:
A Focus on Public Drug Programs
2
About CIHI
Our Vision
Better data. Better decisions. Healthier Canadians.
Our Mandate
To lead the development and maintenance of
comprehensive and integrated health information that
enables sound policy and effective health system
management that improve health and health care.
Our Values
Respect, Integrity, Collaboration, Excellence, Innovation
3
About CIHI’s NPDUIS Database and NHEX Data
CIHI’s National Prescription Drug Utilization
Information System (NPDUIS) Database
provides data on key aspects of public drug
plans in Canada. These include claims and
formulary data, drug product information and
plan information.
CIHI’s National Health Expenditure Database
(NHEX) has been collecting, processing and
analyzing summary data on all health
spending in Canada since 1975. Health
expenditures for the most recent two years
are also forecasted.
Information from the NPDUIS Database is used
to support accurate, timely and comparative
analytic and reporting requirements for the
establishment of sound pharmaceutical policies
and the effective management of Canada’s public
drug benefit programs.
Information from NHEX is used to facilitate
provincial/territorial, national and international
comparative reporting. NHEX information also
supports policy planning, decision-making
and research.
For more information, please contact
Program Lead, National Prescription Drug Utilization Information System Database
Canadian Institute for Health Information
495 Richmond Road, Suite 600
Ottawa, Ontario K2A 4H6
Phone: 613-241-7860
Fax: 613-241-8120
Email: [email protected]
Website: www.cihi.ca
4
In 2013, Canadians spent an estimated
$29.3 billion on prescribed drugs.
Total Health Expenditure, by Use of Funds, Canada, 2013f
5
In 2013, annual growth in prescribed drug
spending was at its second-lowest point in
more than two decades.
Prescribed Drug Spending, Canada, 2001 to 2013f
6
In 2013, 41.6% of prescribed drug spending
was financed by the public sector.
Publicly Funded Drug Spending as a Percentage of Prescribed Drug
Spending, by Source of Finance, by Province and Canada, 2013f
7
Top 10 drug classes accounted for 34.2%
of public drug program spending.
Top 10 Drug Classes by Total Program Spending, Selected Jurisdictions,* 2012
TPS
($ Millions)
Proportion
of TPS (%)
Drug Class
Common Uses
Tumor Necrosis Factor Alpha Inhibitors
(Anti-TNF Drugs)
Rheumatoid Arthritis, Crohn’s Disease
483.4
6.5
HMG-CoA Reductase
Inhibitors (Statins)
High Cholesterol
416.9
5.6
Proton Pump Inhibitors (PPIs)
Gastroesophageal Reflux Disease,
Peptic Ulcer Disease
267.4
3.6
Antineovascularization Agents
Age-Related Macular Degeneration
234.8
3.2
Adrenergics and Other Drugs
for Obstructive Airway Diseases
Asthma, Emphysema,
Chronic Bronchitis
204.9
2.8
Natural Opium Alkaloids
Management of Moderate to
Severe Pain
203.7
2.8
Angiotensin-Converting Enzyme (ACE)
Inhibitors, Plain
Heart Failure, High Blood Pressure
203.5
2.8
Selective Serotonin
Reuptake Inhibitors
Depression
180.8
2.4
Diazepines, Oxazepines,
Thiazepines and Oxepines
Schizophrenia, Bipolar Disorder
166.4
2.3
Other Antidepressants
Depression
162.3
2.2
2,524.3
34.2
Combined Top 10
8
The majority of public drug spending was for a
relatively small number of high-cost individuals.
Percentage of Paid Beneficiaries and Total Drug Program Spending,
by Program Spending per Paid Beneficiary, 2012, Selected Jurisdictions*
Program
Spending
Proportion of
Paid Beneficiaries (%)
Proportion of TPS (%)
<$500
52.1
6.2
$500–$1,499
25.3
18.0
9.9
15.0
12.7
60.8
$1,500–$2,499
≥$2,500
9
Roughly two-thirds of observed growth in total
spending was due to two newer categories
of biologics.
Top 10 Drug Classes by Contribution to Growth, Selected Jurisdictions,*
2007 to 2012
Contribution
to TPS
Growth (%)
Average
Annual
Growth (%)
Drug Class
Common Use
Tumor Necrosis Factor Alpha Inhibitors
(Anti-TNF Drugs)
Rheumatoid Arthritis,
Crohn’s Disease
54.8
28.1
Antineovascularization Agents
Age-Related Macular Degeneration
12.6
129.0
Adrenergics and Other Drugs for
Obstructive Airway Diseases
Asthma, Emphysema,
Chronic Bronchitis
6.7
9.5
Other Antipsychotics
Schizophrenia, Bipolar, Dementia,
Affective Disorder
5.1
14.6
Drugs Used in Opioid Dependence
Drug Addiction, Pain Control
4.6
13.8
Anticholinergics
Emphysema, Chronic Bronchitis
4.2
13.2
Natural Opium Alkaloids
Management of Moderate to
Severe Pain
3.5
4.2
Anticholinesterases
Alzheimer’s Disease
3.4
11.1
Other Antiepileptics
Epilepsy, Pain
3.0
5.2
Selective Serotonin Reuptake
Inhibitors (SSRIs)
Depression, Anxiety, Panic Disorder
2.9
3.5
10
Generic drugs accounted for the majority of use
but less than half of spending.
Percentage Share of Total Drug Program Spending and Number of
Accepted Claims (Brand Name and Generic), Selected Jurisdictions,* 2012
11